Back to Agenda
The Changing Landscape for Bioinnovation: The Emergence of Small Pharma, Strategic Alliances, and Precision Medicine (Part 1 of 2)
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States
The landscape for pharmaceutical R&D is shifting dramatically: From large pharmaceutical companies to small and specialty pharmaceutical companies, from vertically integrated companies to collaborative partnerships and innovation networks, and from high volume markets to targeted and precision medicines. This two-part forum will explore the impact of these changes on the R&D landscape.
This first forum will focus on the small and specialty pharmaceutical company sector as the new engine of bioinnovation, and will look at the role of innovative collaborative partnerships and strategic alliances in the discovery, development, and commercialization of new medical products.
Part 2 will take place on Tuesday at 10:30 AM (Session #252).
Learning Objective : Identify shifts in pharmaceutical R&D; Discuss the impact of these changes on the R&D landscape; Examine the role of small and specialty pharma in the discovery, development, and commercialization of new medical products.
Speaker(s)
Panelist
Kenneth I. Kaitin, PhD
Tufts Center for the Study of Drug Development, United States
Professor and Senior Fellow
Panelist
Ellen G Feigal, MD, MSc
NDA Partners LLC, United States
Principal
Panelist
David G Shoemaker, PhD
Rho, Inc., United States
Senior Vice President, R&D
Panelist
Bruce M. Wagman, MBA, RN, RAC
Labcorp Drug Development, United States
Have an account?